Beyond market trends, investors looking for superior returns explore the world of stock picking. The right selections can be a powerful driver for wealth accumulation.
BioAffinity Technologies Inc (NASDAQ: BIAF) closed the day trading at $2.56 down -1.92% from the previous closing price of $2.61. In other words, the price has decreased by -$1.92 from its previous closing price. On the day, 0.56 million shares were traded. BIAF stock price reached its highest trading level at $2.65 during the session, while it also had its lowest trading level at $2.3401.
Ratios:
For a better understanding of BIAF, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 0.63 and its Current Ratio is at 0.64.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, BIAF now has a Market Capitalization of 7430346 and an Enterprise Value of 2272338. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.62. Its current Enterprise Value per Revenue stands at 0.296 whereas that against EBITDA is -0.239.
Stock Price History:
The Beta on a monthly basis for BIAF is 2.35, which has changed by -0.9512381 over the last 52 weeks, in comparison to a change of 0.1719923 over the same period for the S&P500. Over the past 52 weeks, BIAF has reached a high of $67.12, while it has fallen to a 52-week low of $2.54. The 50-Day Moving Average of the stock is -63.15%, while the 200-Day Moving Average is calculated to be -80.49%.
Shares Statistics:
Over the past 3-months, BIAF traded about 1.82M shares per day on average, while over the past 10 days, BIAF traded about 10660450 shares per day. A total of 1.85M shares are outstanding, with a floating share count of 1.34M. Insiders hold about 27.53% of the company’s shares, while institutions hold 0.65% stake in the company. Shares short for BIAF as of 1757894400 were 111016 with a Short Ratio of 0.06, compared to 1755216000 on 32864. Therefore, it implies a Short% of Shares Outstanding of 111016 and a Short% of Float of 12.75.
Earnings Estimates
. The current rating of BioAffinity Technologies Inc (BIAF) is the result of assessments by 1.0 analysts actively engaged in evaluating its market dynamics.The consensus estimate for the next quarter is -$2.7, with high estimates of -$2.7 and low estimates of -$2.7.
Analysts are recommending an EPS of between -$14.4 and -$14.4 for the fiscal current year, implying an average EPS of -$14.4. EPS for the following year is -$8.1, with 1.0 analysts recommending between -$8.1 and -$8.1.
Revenue Estimates
1 analysts predict $1.41M in revenue for. The current quarter. It ranges from a high estimate of $1.41M to a low estimate of $1.41M. As of. The current estimate, BioAffinity Technologies Inc’s year-ago sales were $2.35MFor the next quarter, 1 analysts are estimating revenue of $1.55M. There is a high estimate of $1.55M for the next quarter, whereas the lowest estimate is $1.55M.
A total of 1 analysts have provided revenue estimates for BIAF’s current fiscal year. The highest revenue estimate was $6.09M, while the lowest revenue estimate was $6.09M, resulting in an average revenue estimate of $6.09M. In the same quarter a year ago, actual revenue was $9.36MBased on 1 analysts’ estimates, the company’s revenue will be $7.31M in the next fiscal year. The high estimate is $7.31M and the low estimate is $7.31M.
